Log in with your email address username.


[Correspondence] Severe asthma and asthma-chronic obstructive pulmonary disease syndrome

We read the excellent work by Sally Wenzel and colleagues (July 2, p 31)1 with great interest. Treatment with dupilumab, a human anti-interleukin-4 receptor α monoclonal antibody, resulted in elevated forced expiratory volume in 1 s (FEV1), improved asthma symptom control, and reduced annual rates of exacerbation in patients with uncontrolled persistent asthma.